A Double-blind, Single-center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer's Disease

Trial Profile

A Double-blind, Single-center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer's Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Medipost
  • Most Recent Events

    • 18 Apr 2017 Planned number of patients changed from 42 to 45.
    • 18 Apr 2017 Planned End Date changed from 1 Feb 2018 to 1 Jul 2019.
    • 18 Apr 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top